全文获取类型
收费全文 | 1383篇 |
免费 | 131篇 |
出版年
2023年 | 9篇 |
2022年 | 19篇 |
2021年 | 28篇 |
2020年 | 20篇 |
2019年 | 23篇 |
2018年 | 24篇 |
2017年 | 21篇 |
2016年 | 37篇 |
2015年 | 82篇 |
2014年 | 91篇 |
2013年 | 101篇 |
2012年 | 151篇 |
2011年 | 122篇 |
2010年 | 113篇 |
2009年 | 83篇 |
2008年 | 85篇 |
2007年 | 93篇 |
2006年 | 92篇 |
2005年 | 70篇 |
2004年 | 74篇 |
2003年 | 57篇 |
2002年 | 60篇 |
2001年 | 8篇 |
2000年 | 3篇 |
1999年 | 9篇 |
1998年 | 9篇 |
1997年 | 3篇 |
1996年 | 6篇 |
1994年 | 5篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1984年 | 2篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1971年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有1514条查询结果,搜索用时 31 毫秒
111.
112.
113.
114.
Johanna Ceschin Hans Caspar Hürlimann Christelle Saint-Marc Delphine Albrecht Typhaine Violo Michel Moenner Bertrand Daignan-Fornier Beno?t Pinson 《The Journal of biological chemistry》2015,290(39):23947-23959
5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside monophosphate (AICAR) is a natural metabolite with potent anti-proliferative and low energy mimetic properties. At high concentration, AICAR is toxic for yeast and mammalian cells, but the molecular basis of this toxicity is poorly understood. Here, we report the identification of yeast purine salvage pathway mutants that are synthetically lethal with AICAR accumulation. Genetic suppression revealed that this synthetic lethality is in part due to low expression of adenine phosphoribosyl transferase under high AICAR conditions. In addition, metabolite profiling points to the AICAR/NTP balance as crucial for optimal utilization of glucose as a carbon source. Indeed, we found that AICAR toxicity in yeast and human cells is alleviated when glucose is replaced by an alternative carbon source. Together, our metabolic analyses unveil the AICAR/NTP balance as a major factor of AICAR antiproliferative effects. 相似文献
115.
Thomas?Durand Sophie?Jacob Laura?Lebouil Hassen?Douzane Philippe?Lestaevel Amithys?Rahimian Dimitri?Psimaras Lo?c?Feuvret Delphine?Leclercq Bruno?Brochet Radia?Tamarat Fabien?Milliat Marc?Benderitter Nicolas?Vayatis Georges?No?l Khê?Hoang-Xuan Jean-Yves?Delattre Damien?Ricard Marie-Odile?BernierEmail author 《BMC neurology》2015,15(1):261
Background
Radiotherapy is one of the most important treatments of primary and metastatic brain tumors. Unfortunately, it can involve moderate to severe complications among which leukoencephalopathy is very frequent and implies cognitive deficits such as memory, attention and executive dysfunctions. However, the incidence of this complication is not well established and the risk factors and process are poorly understood. The main objective of the study is to improve knowledge on radio-induced leukoencephalopathy based on pluridisciplinar approaches combining cognitive, biologic, imagery and dosimetric investigations.Method/Design
The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy. Patients are included between their surgery and first day of radio-chemotherapy, and the follow-up lasts for 3 years after treatment. Cognitive functioning assessments, specific blood biomarkers measures and magnetic resonance imagery are performed at different moment during the follow-up, and a specific dosimetric assessment of organs involved in the beam fields is performed. Firstly, leukoencephalopathy incidence rate will be estimated in this population. Secondly, correlations between cognitive impairments and dosimetry, biomarkers ranges and anomalies on imagery will be analyzed in order to better understand the onset and evolution of cognitive decrement associated with radiotherapy. Furthermore, a new cognitive test, quickly and easily performed, will be studied to determine its sensibility to detect leukoencephalopathy decrement.Discussion
With an original multidisciplinary approach, the EpiBrainRad study aims to improve knowledge on radio-induced leukoencephalopathy in order to improve its early diagnosis and prevention. The main challenge is to preserve quality-of-life after cancer treatments which imply to study the incidence of radiation-induced complications and their associated risk factors.Trial Registration
NCT02544178116.
Lakard B Magnin D Deschaume O Vanlancker G Glinel K Demoustier-Champagne S Nysten B Jonas AM Bertrand P Yunus S 《Biosensors & bioelectronics》2011,26(10):4139-4145
A potentiometric biosensor based on urease was developed for the quantitative determination of urea concentration in aqueous solutions for biomedical applications. The urease was either physisorbed onto an electrodeposited polyaniline film (PANI), or immobilized on a layer-by-layer film (LbL) assembled over the PANI film, that was obtained by the alternate deposition of charged polysaccharides (carboxymethylpullulan (CMP) and chitosan (CHI)). In the latter case, the urease (Urs) enzyme was either physically adsorbed or covalently grafted to the LbL film using carbodiimide coupling reaction. Potentiometric responses of the enzymatic biosensors were measured as a function of the urea concentration in aqueous solutions (from 10(-6) to 10(-1) mol L(-1) urea). Very high sensitivity and short response time were observed for the present biosensor. Moreover, a stability study showed a higher stability over time for the potentiometric response of the sensor with the enzyme-grafted LbL film, testifying for the protective nature of the polysaccharide coating and the interest of covalent grafting. 相似文献
117.
Rawson DJ Brugier D Harrison A Hough J Newman J Otterburn J Maw GN Price J Thompson LR Turnpenny P Warren AN 《Bioorganic & medicinal chemistry letters》2011,21(12):3771-3773
A potent series of substituted (2S,4S)-benzylproline α2δ ligands have been designed from the readily available starting material (2S,4R)-hydroxy-l-proline. The ligands have improved pharmacokinetic profile over the (4S)-phenoxyproline derivatives described previously and have potential for development as oral agents for the treatment of neuropathic pain. Compound 16 has been progressed to clinical development. 相似文献
118.
Berger G Durand S Fargier G Nguyen XN Cordeil S Bouaziz S Muriaux D Darlix JL Cimarelli A 《PLoS pathogens》2011,7(9):e1002221
Myeloid cells play numerous roles in HIV-1 pathogenesis serving as a vehicle for viral spread and as a viral reservoir. Yet, cells of this lineage generally resist HIV-1 infection when compared to cells of other lineages, a phenomenon particularly acute during the early phases of infection. Here, we explore the role of APOBEC3A on these steps. APOBEC3A is a member of the APOBEC3 family that is highly expressed in myeloid cells, but so far lacks a known antiviral effect against retroviruses. Using ectopic expression of APOBEC3A in established cell lines and specific silencing in primary macrophages and dendritic cells, we demonstrate that the pool of APOBEC3A in target cells inhibits the early phases of HIV-1 infection and the spread of replication-competent R5-tropic HIV-1, specifically in cells of myeloid origins. In these cells, APOBEC3A affects the amount of vDNA synthesized over the course of infection. The susceptibility to the antiviral effect of APOBEC3A is conserved among primate lentiviruses, although the viral protein Vpx coded by members of the SIV(SM)/HIV-2 lineage provides partial protection from APOBEC3A during infection. Our results indicate that APOBEC3A is a previously unrecognized antiviral factor that targets primate lentiviruses specifically in myeloid cells and that acts during the early phases of infection directly in target cells. The findings presented here open up new venues on the role of APOBEC3A during HIV infection and pathogenesis, on the role of the cellular context in the regulation of the antiviral activities of members of the APOBEC3 family and more generally on the natural functions of APOBEC3A. 相似文献
119.
Delphine Mariotte Beno?t Dupont Radj Gervais Marie-Pierre Galais Dominique Laroche Aurore Tranchant Elisabeth Comby Karine Bouhier-Leporrier Jean-Marie Reimund Brigitte Le Mauff 《MABS-AUSTIN》2011,3(4):396-401
Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, has proven effective in the treatment of metastatic colorectal cancer and squamous cell carcinoma of the head and neck. However, a high incidence of immediate hypersensitivity reactions (HSR) to cetuximab after the first infusion has been observed. We have developed a test for identification of patients likely to show treatment-related HSR to cetuximab. An enzyme-linked immunosorbent assay (ELISA) for detecting anti-cetuximab IgEs was developed and tested on serum samples collected from cancer patients before start of cetuximab treatment, and from healthy blood donors. Similar levels of anti-cetuximab IgE were detected in pre-treatment patient sera (24/92, 26.1%) and sera from healthy blood donors (33/117, 28.2%). HSR were observed in 14 out of the 92 patients (15.2%), and 8 of these (57.1%) were grade 3–4. Anti-cetuximab IgEs were detected in 7/8 of the patients (87.5%) with severe HSRs as compared with 14/78 patients (17.9%) with no HSR (p = 0.0002). Predictive value of the anti-cetuximab IgE test for HSR events of grades 3–4 was calculated using Receiver Operating Characteristics analysis. With a cut-off value of 29 arbitrary units for the anti-cetuximab IgE, the ELISA test showed a sensitivity of 87.5%, specificity of 82.1%, positive predictive value of 33.3% and negative predictive value of 98.5%. Anti-cetuximab IgE ELISA detection could be a valuable tool to help the physician anticipate an anaphylaxis episode following cetuximab infusion and opt for a suitable alternative treatment.Key words: anti-cetuximab antibodies, ELISA, hypersensitivity, therapeutic monoclonal antibody, ROC 相似文献
120.
Wills M Akbar A Beswick M Bosch JA Caruso C Colonna-Romano G Dutta A Franceschi C Fulop T Gkrania-Klotsas E Goronzy J Griffiths SJ Henson S Herndler-Brandstetter D Hill A Kern F Klenerman P Macallan D Macualay R Maier AB Mason G Melzer D Morgan M Moss P Nikolich-Zugich J Pachnio A Riddell N Roberts R Sansoni P Sauce D Sinclair J Solana R Strindhall J Trzonkowski P van Lier R Vescovini R Wang G Westendorp R Pawelec G 《Immunity & ageing : I & A》2011,8(1):10-8
The Second International Workshop on CMV & Immunosenescence was held in Cambridge, UK, 2-4th December, 2010. The presentations covered four separate sessions: cytomegalovirus and T cell phenotypes; T cell memory frequency, inflation and immunosenescence; cytomegalovirus in aging, mortality and disease states; and the immunobiology of cytomegalovirus-specific T cells and effects of the virus on vaccination. This commentary summarizes the major findings of these presentations and references subsequently published work from the presenter laboratory where appropriate and draws together major themes that were subsequently discussed along with new areas of interest that were highlighted by this discussion. 相似文献